Foundayo vs the Wegovy pill: how the two GLP-1 pills compare in 2026

The Wegovy pill and Foundayo are the two GLP-1 pills the FDA has approved for weight management, and the practical difference between them comes down to three things: the Wegovy pill (oral semaglutide, 25 mg) showed somewhat more weight loss in its trial and carries a cardiovascular indication, while Foundayo (orforglipron) can be taken at any time of day with or without food and has no empty-stomach rule. They have never been compared head to head, their side effects are the same family of stomach and bowel effects, and both carry the GLP-1 class boxed warning about thyroid C-cell tumors. Here is what each product’s prescribing information and main trial actually say, so you can have a sharper conversation with whoever prescribes for you.

A peptide pill and a small-molecule pill: why that matters

Semaglutide is a peptide, a short chain of amino acids, and the gut digests peptides the way it digests food. The Wegovy tablet gets around that by pairing semaglutide with an absorption enhancer, and the rules in its prescribing information exist to let enough of it through: take it first thing in the morning on an empty stomach, with no more than 4 ounces of plain water and no other liquid, swallow it whole, then wait at least 30 minutes before eating, drinking or taking any other oral medication. Even then only a small fraction is absorbed, which is why the tablet strengths read in the tens of milligrams while the weekly injection tops out at 2.4 mg. Skip the fasting rule and you may simply get less medicine.

Orforglipron is a different kind of molecule. The ATTAIN-1 paper describes it as a small-molecule, non-peptide GLP-1 receptor agonist, meaning it is built like a conventional pill rather than a hormone, and it survives digestion on its own. Lilly’s prescribing information says to take it once daily with or without food, at any time, swallowed whole. That is the single biggest practical difference between the two, and for someone who takes other morning medications, works nights or cannot face a 30-minute wait before coffee, it is often the deciding one.

Foundayo pays for that convenience with a longer drug-interaction list. Because it is cleared through the liver enzyme CYP3A4, its label caps the dose at 9 mg with strong CYP3A4 inhibitors such as clarithromycin, says to avoid ritonavir and strong inducers such as carbamazepine, limits simvastatin to 20 mg a day, and tells people on oral hormonal contraceptives to switch to a non-oral method or add a barrier method for 30 days after starting and for 30 days after each dose increase. The Wegovy pill’s interactions are mostly about timing, since it must be taken alone, plus the class-wide effect of slowed stomach emptying on other oral medicines. Either way, the prescriber needs your full medication list.

How much weight did each pill produce in its trial?

The Wegovy pill was tested in OASIS 4, published in the New England Journal of Medicine in September 2025 and listed as Study 7 in the Wegovy label: 307 adults without diabetes who had obesity, or overweight with a weight-related condition, took 25 mg of oral semaglutide or placebo for 64 weeks. The label reports an average loss of 13.6% of body weight against 2.4% on placebo. In the paper, the analysis that counts everyone regardless of whether they kept taking the pill gives 13.6% against 2.2%, and the analysis limited to people who stayed on treatment gives 16.6% against 2.7%. By the label’s count, 59.8% of people on the pill lost at least 10% of their body weight, 47% lost at least 15% and 27.9% lost at least 20%, against 14.4%, 5.5% and 3.1% on placebo.

Foundayo was tested in ATTAIN-1, published in the same journal the same month: 3,127 adults with obesity and no diabetes, randomized to one of three doses or placebo for 72 weeks. On the top dose the average loss was 11.2% against 2.1% on placebo, using the trial’s primary analysis, which counts people whether or not they stayed on treatment. The 12.4% figure that appears in Lilly’s announcement is the paper’s secondary analysis estimating what would have happened if everyone had stayed on the pill. At the top dose, 54.6% lost at least 10% of their body weight, 36.0% lost at least 15% and 18.4% lost at least 20%, against 12.9%, 5.9% and 2.8% on placebo. The trial used doses labeled 6, 12 and 36 mg; the marketed tablets use a different strength scale, and the prescribing information reports the same trial under those strengths, with 11.1% at 17.2 mg.

It is tempting to read those two paragraphs as the Wegovy pill winning by about two points. Be careful. The trials differed in size (307 people against 3,127), length (64 weeks against 72), and who enrolled (OASIS 4 was 79% women and 92% White; ATTAIN-1 was 64% women and 57% White, with a large Asian cohort). No trial has put the two pills in the same room. What both share is that they landed below the weekly injections in their own trials: Wegovy injection produced 14.9% in STEP 1 and Zepbound 20.9% in SURMOUNT-1, as our semaglutide vs tirzepatide guide explains. If the most weight loss the evidence supports is your priority, the pills are not where that evidence points; if avoiding a needle is the priority, both pills are real options, and our Wegovy alternatives guide puts them next to every other choice.

Side effects: the same family, different counts

Both pills cause the stomach and bowel effects every GLP-1 medicine causes, mostly mild to moderate, clustered in the weeks after each dose increase. Foundayo’s prescribing information pools its two main trials and lists, at the 17.2 mg dose against placebo:

• Nausea: 35% vs 10%
• Diarrhea: 25% vs 11%
• Vomiting: 24% vs 4%
• Constipation: 24% vs 9%
• Abdominal pain: 14% vs 7%
• Indigestion: 13% vs 4%
• Headache: 9% vs 7%
• Fatigue: 9% vs 4%

The Wegovy label does not print a separate side-effect table for the tablet; it says the types and frequency of common reactions in the tablet trial were similar to the injection’s, where nausea affected 44% of people in STEP 1. The OASIS 4 paper reports that 74% of people on the pill had a gastrointestinal adverse event against 42% on placebo. One effect worth knowing about is dysesthesia, odd skin sensations such as tingling or burning, reported by 5% of people on the tablet and none on placebo; in ATTAIN-1 it was 1.2% on the top Foundayo dose against 0.6% on placebo.

On quitting: adverse reactions led 6.8% of people on the Wegovy pill to stop, against 5.9% on placebo, per the label. In ATTAIN-1, adverse events led 5.3% to 10.3% of people on Foundayo to stop depending on dose, against 2.7% on placebo, and stomach and bowel effects specifically drove 3.5% to 7.0% of those exits against 0.4%. Serious adverse events in ATTAIN-1 ran 3.8% to 5.5% on Foundayo and 4.9% on placebo; five cases of mild pancreatitis were confirmed, all in the orforglipron groups. Both labels carry the class warnings for pancreatitis, gallbladder disease, kidney injury from dehydration, low blood sugar when combined with insulin or sulfonylureas, and the risk of stomach contents being inhaled under anesthesia, which is why both say to tell your surgical team before a procedure. If side effects are what pushed you off an injection, our guide to Wegovy alternatives with fewer side effects covers the levers that usually matter more than the molecule.

The boxed warning on both

Each label opens with a boxed warning about thyroid C-cell tumors, and each product is contraindicated for anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. The basis is rodent studies: semaglutide caused dose-dependent thyroid C-cell tumors in rats and mice. Foundayo’s label makes an unusual admission here. Orforglipron is not pharmacologically active in rats or mice and did not produce tumors in them; the warning is carried because every GLP-1 receptor agonist that is active in rodents has, and whether any of this applies to humans has not been determined. Both labels say to report a neck lump, trouble swallowing, shortness of breath or persistent hoarseness.

Heart data: where the Wegovy pill has something Foundayo does not

The Wegovy tablet is approved not only for weight reduction but to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal heart attack and non-fatal stroke) in adults with established cardiovascular disease and obesity or overweight. That indication rests on SELECT, a trial of the weekly 2.4 mg injection in 17,604 adults, in which those events occurred in 6.5% of people on semaglutide against 8.0% on placebo, roughly a 20% relative reduction. Novo Nordisk’s approval announcement says the pill’s approval drew on both the OASIS trials and SELECT, and the label lets people already on the injection for cardiovascular risk reduction switch to the 25 mg tablet.

Foundayo’s label covers weight reduction only. ATTAIN-1 did show improvements in waist circumference, systolic blood pressure, triglycerides and non-HDL cholesterol compared with placebo, and the number of adjudicated cardiovascular events over 72 weeks was small in every group, but a 72-week weight trial is not built to prove protection from heart attacks and strokes. For someone who already has heart disease, this is the fact a prescriber will weigh most heavily.

Dose steps, and what happens if you miss a day

The Wegovy pill’s label schedule is 1.5 mg once daily for the first 30 days, 4 mg for the next 30, 9 mg for the next 30, then 25 mg from day 91 onward as the maintenance dose. If 25 mg is not tolerated, the label suggests considering the 1.7 mg weekly injection instead. A missed tablet is skipped; you take the next one the following morning rather than doubling up. Someone moving from the injection takes the first 25 mg tablet one week after the last 2.4 mg shot.

Foundayo starts at 0.8 mg once daily, moves to 2.5 mg after at least 30 days and to 5.5 mg after at least 30 more. From there the label leaves the next step to response and tolerability: a person may stay at 5.5 mg or move to 9, 14.5 or 17.2 mg, each after at least 30 days on the previous strength, with 17.2 mg the maximum. There is no single maintenance dose. A missed tablet is taken as soon as you remember, without doubling the next day; after seven or more missed days in a row, the label says to restart the escalation at a lower strength. The practical upshot is that reaching the top of Foundayo’s ladder takes about five months against three for the Wegovy pill, and in both cases a prescriber can hold a step longer when side effects flare. These are the labels’ schedules; your own schedule is whatever your prescriber sets.

Who might lean which way

• You already have heart disease: the Wegovy pill’s cardiovascular indication is the fact to raise, because Foundayo’s label carries no such indication.
• A fasting morning routine will not survive your life: shift work, breakfast-first habits, or morning medicines such as thyroid hormone that also want an empty stomach make Foundayo’s any-time dosing the practical choice.
• You take an oral contraceptive, simvastatin, certain antibiotics or antifungals, or HIV medicines: Foundayo’s interaction list needs a careful review, and the Wegovy pill may be simpler.
• Semaglutide did not agree with you: Foundayo is a different molecule in the same class, so the side effects overlap heavily; some people do better, and the trials give no guarantee either way.
• You want the most weight loss the evidence supports: in their own trials both pills landed below the weekly injections, and tirzepatide remains the best-supported option on that measure.
• You simply cannot do needles: either pill is a legitimate route, and the choice turns on the points above.

None of this is a self-selection exercise. Both medicines are prescription-only, both are ruled out by the thyroid history above and by pregnancy, and a licensed provider has to weigh your other conditions and medicines before either is appropriate.

Where compounded medication fits, and where it does not

StaveMD does not offer Foundayo or the Wegovy pill. Both are brand-name products made by Lilly and Novo Nordisk and dispensed through retail pharmacies and the manufacturers’ own channels. What a StaveMD provider may prescribe, when they judge it clinically appropriate, is compounded semaglutide or compounded tirzepatide, prepared for an individual prescription by a licensed compounding pharmacy, as a weekly injection or, for semaglutide, as a daily tablet. These are different finished products: not FDA-approved, not Wegovy, not Foundayo, not a generic and not a substitute, and the trial results on this page belong to the brand products, not to any compounded preparation. The useful order of questions is whether any GLP-1 medicine is appropriate for you, then which one, then which form; our compounded semaglutide page and is compounded GLP-1 legit cover what to ask about the pharmacy and the prescriber before you decide.

Questions people ask about Foundayo and the Wegovy pill

• Is Foundayo better than the Wegovy pill? No trial has compared them. The Wegovy pill produced 13.6% average weight loss over 64 weeks in OASIS 4 and Foundayo 11.2% over 72 weeks at its top dose in ATTAIN-1, but those are different trials with different people, so the two-point gap is a hint, not a verdict.
• Can you take Foundayo with food? Yes. Its label says once daily, any time of day, with or without food. The Wegovy pill must be taken on an empty stomach in the morning with up to 4 ounces of water, followed by a 30-minute wait.
• Which pill has fewer side effects? Neither label supports a clean answer. Both cause nausea, vomiting, diarrhea and constipation at rates well above placebo. In ATTAIN-1, 10.3% of people on the top Foundayo dose stopped for side effects against 2.7% on placebo; in OASIS 4, 6.8% stopped on the Wegovy pill against 5.9% on placebo. Different trials, different placebo rates, no comparison.
• Can you switch from the Wegovy injection to the Wegovy pill? The label describes it: one week after the last 2.4 mg injection, the 25 mg tablet starts, and people on the pill who cannot tolerate 25 mg may be moved to the 1.7 mg injection. Whether to switch, and how, is the prescriber’s call.
• Are the pills FDA-approved? Yes, both the Wegovy pill and Foundayo are FDA-approved brand products. Compounded semaglutide tablets are not FDA-approved and are not the Wegovy pill.
• Why does Foundayo carry a thyroid warning if it is not a peptide? Because every GLP-1 receptor agonist does. Its label notes that orforglipron is not active in rodents and did not cause tumors in them, and that the relevance to humans is undetermined; the contraindication for medullary thyroid cancer history still applies.